Journal of Cancer Treatment and Research

| Peer-Reviewed |

Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells

Received: Nov. 14, 2018    Accepted: Dec. 05, 2018    Published: Jan. 15, 2019
Views:       Downloads:

Share This Article

Abstract

OBJECTIVE: To investigate expression of VEGF of SKBR-3 breast cancer cells in different estrogen and to investigate the expression of VEGF after Bevacizumab, Trastuzumab, Taxol and Insulin-like growth factor 1 receptor (IGF-1R)antibodies treatment in different estrogen. METHODS: RT-PCR was used to detect the expression of VEGF in SKBR-3 breast cancer cells under different concentrations of estrogen and VEGF monoclonal antibody, HER-2 monoclonal antibody, paclitaxel and IGF-1R antibody. At the same time, ELISA was used to detect the concentration of VEGF protein in the culture supernatant. RESULTS: The expression of VEGF in no estrogen group was 1.0618±0.0085 (VEGF/GAPDH); the expression of VEGF in low concentration group (50pg/L) was 1.0047±0.0061, the difference was statistically significant compared with the no estrogen group (P=0.002); the expression of VEGF in high concentration group (0.2 μg/mL) was 1.0868±0.0135, the difference was statistically significant compared with the no estrogen group (P<0.001). The expression of VEGF were 1.0496±0.0288 and 1.0618±0.0085 in Taxol group and contral Group (F=0.058), the expression of VEGF were 1.0884±0.0036, 1.0618 ±0.0085 in antibody of IGF-1R group and contral group (F=0.073), the expression of VEGF were 0.9887±0.0037, 1.0618±0.0085 in Trastuzumab group and contral group (F=0.075). The expression of VEGF in the paclitaxel group and the control group were 1.0496±0.0288 and 1.0618±0.0085(F=0.058);The expression of VEGF in IGF-1R group and control group were 1.0884±0.0036 and 1.0618±0.0085(F=0.073);The expression of VEGF in the trastuzumab group and the control group were 0.9887±0.0037 and 1.0618±0.0085(F=0.075); There was no significant change in the expression of VEGF in the paclitaxel group, the IGF-1R group antibody and the trastuzumab group with estrogen. The expression of VEGF in the bevacizumab group and the control group were 1.0057±0.0043 and 1.0618±0.0085( F=0.132, P=0.04), and There is no synergistic effect of estrogen and VEGF monoclonal antibody on the expression of VEGF. Conclusion: The influence of different estrogen on VEGF-expression in SKBR-3 breast cancer cells is remarkable. Taxol, antibody of IGF-1R and Trastuzumab do not change the expression of VEGF in SKBR-3 breast cancer cells, and this has no synergistic effect with estrogen.. Bevacizumab increases the expression of VEGF, and this also has no synergistic effect with estrogen.

DOI 10.11648/j.jctr.20180604.11
Published in Journal of Cancer Treatment and Research ( Volume 6, Issue 4, December 2018 )
Page(s) 54-59
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

SKBR-3 Breast Cancer Cell Line, Estrogen, Bevacizumab, Vascular Endothelial Growth Factor, IGF-1R Antibody, Trastuzumab

References
[1] Folkman J. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3, 65-71 [J]. Seminars in Cancer Biology, 1992, 3(2): 65-71.
[2] Zhu Liangjie. Correlation between vascular endothelial growth factor levels and lung cancer and breast cancer [J]. China Minkang Medicine, 2017, 29 (20): 36-37.
[3] Bausero P, Benmahdi M, Mazucatelli J, et al. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. [J]. Am J Physiol Heart Circ Physiol, 2000, 279(5): H2033.
[4] Li Hua, Sun Hong. Effects of estrogen and progesterone on the expression of VEGF mRNA in ovarian cancer cells [J]. Chinese Journal of Oncology, 2004, 26(5): 11-14.
[5] Sengupta K, Banerjee S, Saxena N, et al. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway [J]. International Journal of Oncology, 2003, 22(3): 609-614.
[6] Sengupta K, Banerjee S, Saxena N K, et al. Differential expression of VEGF-A mRNA by 17beta-estradiol in breast tumor cells lacking classical ER-alpha may be mediated through a variant form of ER-alpha. [J]. Molecular & Cellular Biochemistry, 2004, 262(1-2): 215-224.
[7] Buteaulozano H, Ancelin M, Lardeux B, et al. Transcriptional Regulation of Vascular Endothelial Growth Factor by Estradiol and Tamoxifen in Breast Cancer Cells A Complex Interplay between Estrogen Receptors α and β [J]. Cancer Research, 2002, 62(17): 4977.
[8] Johns A, Freay AD, Fraser W, et al. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice [J]. Endocrinology, 1996, 137(10): 4511-4513.
[9] Xiong Zhihong, Ding Lihua, Yang Shuxing, et al. Construction of reporter gene containing VEGF promoter and effects of estrogen receptor on its activity [J]. Biotechnology Communication, 2007, 18(6): 915-917.
[10] Klos K S, Wyszomierski S L, Sun M, et al. ErbB2 Increases Vascular Endothelial Growth Factor Protein Synthesis via Activation of Mammalian Target of Rapamycin/p70S6K Leading to Increased Angiogenesis and Spontaneous Metastasis of Human Breast Cancer Cells [J]. Cancer Research, 2006, 66(4): 2028-2037.
[11] Finkenzeller G, Weindel K, Zimmermann W, et al. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1 [J]. Angiogenesis, 2004, 7(1): 59-68.
[12] Read L D, Jr K D, Slamon D J, et al. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines [J]. Cancer Research, 1990, 50(13): 3947-3951.
[13] Wang Junfang. The application effect of paclitaxel in the chemotherapy of breast cancer [J]. Strait Pharmaceutical, 2018, 30(08): 153-154.
[14] Volk L D, Flister M J, Bivens C M, et al. Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti–Vascular Endothelial Growth Factor A Therapy [J]. Neoplasia, 2008, 10(6): 613-623.
[15] Wang Qing, Zhai Fang, Wang Ning, et al. Correlation between ER and HER-2 expression status in late breast cancer and recent effective rate of TE regimen chemotherapy [J]. Journal of Medical Research, 2010, 39(4): 22-25.
[16] Reiss K, D'Ambrosio C, Tu X, et al. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. [J]. Clinical Cancer Research An Official Journal of the American Association for Cancer Research, 1998, 4(11): 2647-2655.
[17] Beckert S, Farrahi F, Perveen Ghani Q, et al. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly (ADP-ribose) polymerase. [J]. Biochemical & Biophysical Research Communications, 2006, 341(1): 67-72.
[18] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
[19] Zhang Honghuan. Therapeutic effect of trastuzumab in the treatment of 40 cases of Her-2 positive breast cancer [J]. Chinese and foreign women's health research, 2018 (18): 112 + 115.
[20] Tsai PW, Shiah SG, Lin MT, Wu CW, Kuo ML. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. [J]. The Journal of Biological Chemistry, 2003, 278(8): 5750-5759.
[21] Robert N J, Dieras V, Glaspy J A, et al. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer [J]. Journal of Clinical Oncology, 2011, 29(10): 1252-1260.
[22] Chen Lijia. Clinical efficacy of bevacizumab combined with TP regimen in the treatment of advanced HER2-negative breast cancer and its effect on related cytokine levels [J]. Labeled Immunoassays and Clinical Medicine, 2018, 25(07): 963-965 +986.
Cite This Article
  • APA Style

    Zinan Wang, Dezhong Zhao, Ruobing Liu, Bin Zheng. (2019). Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells. Journal of Cancer Treatment and Research, 6(4), 54-59. https://doi.org/10.11648/j.jctr.20180604.11

    Copy | Download

    ACS Style

    Zinan Wang; Dezhong Zhao; Ruobing Liu; Bin Zheng. Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells. J. Cancer Treat. Res. 2019, 6(4), 54-59. doi: 10.11648/j.jctr.20180604.11

    Copy | Download

    AMA Style

    Zinan Wang, Dezhong Zhao, Ruobing Liu, Bin Zheng. Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells. J Cancer Treat Res. 2019;6(4):54-59. doi: 10.11648/j.jctr.20180604.11

    Copy | Download

  • @article{10.11648/j.jctr.20180604.11,
      author = {Zinan Wang and Dezhong Zhao and Ruobing Liu and Bin Zheng},
      title = {Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells},
      journal = {Journal of Cancer Treatment and Research},
      volume = {6},
      number = {4},
      pages = {54-59},
      doi = {10.11648/j.jctr.20180604.11},
      url = {https://doi.org/10.11648/j.jctr.20180604.11},
      eprint = {https://download.sciencepg.com/pdf/10.11648.j.jctr.20180604.11},
      abstract = {OBJECTIVE: To investigate expression of VEGF of SKBR-3 breast cancer cells in different estrogen and to investigate the expression of VEGF after Bevacizumab, Trastuzumab, Taxol and Insulin-like growth factor 1 receptor (IGF-1R)antibodies treatment in different estrogen. METHODS: RT-PCR was used to detect the expression of VEGF in SKBR-3 breast cancer cells under different concentrations of estrogen and VEGF monoclonal antibody, HER-2 monoclonal antibody, paclitaxel and IGF-1R antibody. At the same time, ELISA was used to detect the concentration of VEGF protein in the culture supernatant. RESULTS: The expression of VEGF in no estrogen group was 1.0618±0.0085 (VEGF/GAPDH); the expression of VEGF in low concentration group (50pg/L) was 1.0047±0.0061, the difference was statistically significant compared with the no estrogen group (P=0.002); the expression of VEGF in high concentration group (0.2 μg/mL) was 1.0868±0.0135, the difference was statistically significant compared with the no estrogen group (P<0.001). The expression of VEGF were 1.0496±0.0288 and 1.0618±0.0085 in Taxol group and contral Group (F=0.058), the expression of VEGF were 1.0884±0.0036, 1.0618 ±0.0085 in antibody of IGF-1R group and contral group (F=0.073), the expression of VEGF were 0.9887±0.0037, 1.0618±0.0085 in Trastuzumab group and contral group (F=0.075). The expression of VEGF in the paclitaxel group and the control group were 1.0496±0.0288 and 1.0618±0.0085(F=0.058);The expression of VEGF in IGF-1R group and control group were 1.0884±0.0036 and 1.0618±0.0085(F=0.073);The expression of VEGF in the trastuzumab group and the control group were 0.9887±0.0037 and 1.0618±0.0085(F=0.075); There was no significant change in the expression of VEGF in the paclitaxel group, the IGF-1R group antibody and the trastuzumab group with estrogen. The expression of VEGF in the bevacizumab group and the control group were 1.0057±0.0043 and 1.0618±0.0085( F=0.132, P=0.04), and There is no synergistic effect of estrogen and VEGF monoclonal antibody on the expression of VEGF. Conclusion: The influence of different estrogen on VEGF-expression in SKBR-3 breast cancer cells is remarkable. Taxol, antibody of IGF-1R and Trastuzumab do not change the expression of VEGF in SKBR-3 breast cancer cells, and this has no synergistic effect with estrogen.. Bevacizumab increases the expression of VEGF, and this also has no synergistic effect with estrogen.},
     year = {2019}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Influence of Estrogen, Bevacizumab and Other Factors on VEGF Expression in SKBR-3 Breast Cancer Cells
    AU  - Zinan Wang
    AU  - Dezhong Zhao
    AU  - Ruobing Liu
    AU  - Bin Zheng
    Y1  - 2019/01/15
    PY  - 2019
    N1  - https://doi.org/10.11648/j.jctr.20180604.11
    DO  - 10.11648/j.jctr.20180604.11
    T2  - Journal of Cancer Treatment and Research
    JF  - Journal of Cancer Treatment and Research
    JO  - Journal of Cancer Treatment and Research
    SP  - 54
    EP  - 59
    PB  - Science Publishing Group
    SN  - 2376-7790
    UR  - https://doi.org/10.11648/j.jctr.20180604.11
    AB  - OBJECTIVE: To investigate expression of VEGF of SKBR-3 breast cancer cells in different estrogen and to investigate the expression of VEGF after Bevacizumab, Trastuzumab, Taxol and Insulin-like growth factor 1 receptor (IGF-1R)antibodies treatment in different estrogen. METHODS: RT-PCR was used to detect the expression of VEGF in SKBR-3 breast cancer cells under different concentrations of estrogen and VEGF monoclonal antibody, HER-2 monoclonal antibody, paclitaxel and IGF-1R antibody. At the same time, ELISA was used to detect the concentration of VEGF protein in the culture supernatant. RESULTS: The expression of VEGF in no estrogen group was 1.0618±0.0085 (VEGF/GAPDH); the expression of VEGF in low concentration group (50pg/L) was 1.0047±0.0061, the difference was statistically significant compared with the no estrogen group (P=0.002); the expression of VEGF in high concentration group (0.2 μg/mL) was 1.0868±0.0135, the difference was statistically significant compared with the no estrogen group (P<0.001). The expression of VEGF were 1.0496±0.0288 and 1.0618±0.0085 in Taxol group and contral Group (F=0.058), the expression of VEGF were 1.0884±0.0036, 1.0618 ±0.0085 in antibody of IGF-1R group and contral group (F=0.073), the expression of VEGF were 0.9887±0.0037, 1.0618±0.0085 in Trastuzumab group and contral group (F=0.075). The expression of VEGF in the paclitaxel group and the control group were 1.0496±0.0288 and 1.0618±0.0085(F=0.058);The expression of VEGF in IGF-1R group and control group were 1.0884±0.0036 and 1.0618±0.0085(F=0.073);The expression of VEGF in the trastuzumab group and the control group were 0.9887±0.0037 and 1.0618±0.0085(F=0.075); There was no significant change in the expression of VEGF in the paclitaxel group, the IGF-1R group antibody and the trastuzumab group with estrogen. The expression of VEGF in the bevacizumab group and the control group were 1.0057±0.0043 and 1.0618±0.0085( F=0.132, P=0.04), and There is no synergistic effect of estrogen and VEGF monoclonal antibody on the expression of VEGF. Conclusion: The influence of different estrogen on VEGF-expression in SKBR-3 breast cancer cells is remarkable. Taxol, antibody of IGF-1R and Trastuzumab do not change the expression of VEGF in SKBR-3 breast cancer cells, and this has no synergistic effect with estrogen.. Bevacizumab increases the expression of VEGF, and this also has no synergistic effect with estrogen.
    VL  - 6
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Department of Breast, Yan’an Hospital of Kunming City, Kunming, China

  • Department of Breast, Yan’an Hospital of Kunming City, Kunming, China

  • Department of Breast, Yan’an Hospital of Kunming City, Kunming, China

  • Department of Breast, Yan’an Hospital of Kunming City, Kunming, China

  • Section